Close
Help
Need Help?



Get answers in real time with Libertas live chat

Posted Tue, Mar, 26,2013

Receive answers to your questions in real time with Libertas live chat. Connect to all members of our team regardless of location and avoid delays that can occur in email communication.Libertas live chat works like an instant messaging service. From any Libertas webpage simply click on the “Need help?”  button, fill in the required information and start your chat.Efficiently recei...

Continue Reading →

Review of Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration

Posted Tue, Mar, 26,2013

Published today in Clinical Medicine Insights: Therapeutics is a new review by Michael W. Stewart.  Read more about this paper below:TitleReview of Aflibercept for the Treatment of Neovascular Age-Related Macular DegenerationAbstractThe treatment of exudative age-related macular degeneration (AMD) has been completely transformed by the development of drugs that bind vascular endothelial growt...

Continue Reading →

Posted in: Articles Published

Fertility Preservation in Gynecological Cancers

Posted Fri, Mar, 22,2013

Published today in Clinical Medicine Insights: Reproductive Health is a new review by Shakuntala Chhabra and Imran Kutchi.  Read more about this paper below:TitleFertility Preservation in Gynecological CancersAbstractFor cancers of reproductive system in women, fertility preservation is complex. Fertility is also affected by therapies, however prevention is possible. Radiotherapy affects gona...

Continue Reading →

Posted in: Articles Published

ST Elevation in ACS

Posted Fri, Mar, 22,2013

Published today in Clinical Medicine Insights: Case Reports is a new case report by Antoine Kossaify.  Read more about this paper below:TitleST Segment Elevation in aVR: Clinical Significance in Acute Coronary SyndromeAbstractA 59-year-old-male patient with no previous medical history presented with oppressive chest pain; initial electrocardiogram showed ST segment elevation in aVR and V1, wi...

Continue Reading →

Posted in: Articles Published

Follow Libertas on Twitter

Posted Thu, Mar, 21,2013

Follow @la_press and stay up to date with the latest medical and scientific articles with ease. With 40 different category feeds and a selection of news feeds @la_press allows you to receive timely announcements of both new and forthcoming articles.Receive updates on newly published papers, journal developments and calls for papers directly to your news stream. Missed an article? We have you cover...

Continue Reading →

Posted in: Social Media

Safety and Efficacy of Fidaxomicin

Posted Thu, Mar, 21,2013

Published today in Clinical Medicine Insights: Therapeutics is a new review by Monica A. Donnelley, Jeremiah J. Duby, and Christine S. Cocanour.  Read more about this paper below:TitleSafety and Efficacy of Fidaxomicin in Patients With Clostridium Difficile InfectionAbstractFidaxomicin is a bactericidal macrolide that is indicated for the treatment of Clostridium difficile infection (CDI) in ...

Continue Reading →

Posted in: Articles Published

Our Service Promise

  • Prompt Processing (3 Weeks to Editorial Decision)
  • Fair, Independent Peer Review
  • High Visibility & Extensive Indexing
What Your Colleagues Say About Libertas Academica
I would like to echo the endorsement of Dr. Yi Hong Zhou of UC Irvine, the corresponding author on our paper in Biomarker Insights.  We found that reviewers provided reviews quickly without sacrificing professionalism.  And overall, we were very happy with our experience with Libertas Academica.
Eric R. Siegel (Research Associate, Department of Biostatistics, University of Arkansas for Medical Sciences)
More Testimonials

Quick Links




Follow Us We make it easy to find new research papers.




SUBJECT HUBS
Author Survey Results
author_survey_results
All authors are surveyed after their articles are published. Authors are asked to rate their experience in a variety of areas, and their responses help us to monitor our performance. Presented here are their responses in some key areas. No 'poor' or 'very poor' responses were received; these are represented in the 'other' category.
See Our Results